AdooQ BioScience is a supplier of biochemicals located in Irvine, CA since 2006. In the past five years, we have been a renowned name engaged in manufacturing and supplying small molecule inhibitors including kinase inhibitors on kinds of signal pathway, such as PI3K, AKT, HDAC, MARP etc.
Company WebsiteA-582941 is a selective AChR a7 partial agonist. It exhibits high affinity for both rat and human a7 receptors (Ki values are 10.8 and 16.7 nM, respectively).
More Information Supplier PageA-674563 is a B/Akt inhibitor with an IC50 of 14 nM and also shows inhibitory activity against PKA and CDK2 with IC50 of 16 and 46 nM, respectively.
More Information Supplier PageA-674563 is a B/Akt inhibitor with an IC50 of 14 nM and also shows inhibitory activity against PKA and CDK2 with IC50 of 16 and 46 nM, respectively.
More Information Supplier PageA-674563 is a B/Akt inhibitor with an IC50 of 14 nM and also shows inhibitory activity against PKA and CDK2 with IC50 of 16 and 46 nM, respectively.
More Information Supplier PageA-674563 is a B/Akt inhibitor with an IC50 of 14 nM and also shows inhibitory activity against PKA and CDK2 with IC50 of 16 and 46 nM, respectively.
More Information Supplier PageA-674563 is a B/Akt inhibitor with an IC50 of 14 nM and also shows inhibitory activity against PKA and CDK2 with IC50 of 16 and 46 nM, respectively.
More Information Supplier PageA 841720 is a potent, non-competitive mGluR-1 antagonist that displays 34-fold selectivity over mGluR-5 (IC50 values are 10 and 342 nM respectively).
More Information Supplier PageA 841720 is a potent, non-competitive mGluR-1 antagonist that displays 34-fold selectivity over mGluR-5 (IC50 values are 10 and 342 nM respectively).
More Information Supplier PageA 841720 is a potent, non-competitive mGluR-1 antagonist that displays 34-fold selectivity over mGluR-5 (IC50 values are 10 and 342 nM respectively).
More Information Supplier PageA-867744 is a novel positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor.
More Information Supplier PageA-867744 is a novel positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor.
More Information Supplier PageA-867744 is a novel positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor.
More Information Supplier PageA-867744 is a novel positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor.
More Information Supplier PageA-889425 is a selective TRPV1 receptor antagonist. A-889425 blocks TRPV1 channels with an IC50 of 335 nM (rat) and 34 nM (human).
More Information Supplier PageA-889425 is a selective TRPV1 receptor antagonist. A-889425 blocks TRPV1 channels with an IC50 of 335 nM (rat) and 34 nM (human).
More Information Supplier PageA-889425 is a selective TRPV1 receptor antagonist. A-889425 blocks TRPV1 channels with an IC50 of 335 nM (rat) and 34 nM (human).
More Information Supplier PageA-966492 displayed high potency against the poly(ADP-ribose) polymerase-1 (PARP-1) enzyme with a K(i) of 1 nM and an EC(50) of 1 nM in a whole cell assay.
More Information Supplier PageA-966492 displayed high potency against the poly(ADP-ribose) polymerase-1 (PARP-1) enzyme with a K(i) of 1 nM and an EC(50) of 1 nM in a whole cell assay.
More Information Supplier PageA-966492 displayed high potency against the poly(ADP-ribose) polymerase-1 (PARP-1) enzyme with a K(i) of 1 nM and an EC(50) of 1 nM in a whole cell assay.
More Information Supplier PageA-966492 displayed high potency against the poly(ADP-ribose) polymerase-1 (PARP-1) enzyme with a K(i) of 1 nM and an EC(50) of 1 nM in a whole cell assay.
More Information Supplier PageA-966492 displayed high potency against the poly(ADP-ribose) polymerase-1 (PARP-1) enzyme with a K(i) of 1 nM and an EC(50) of 1 nM in a whole cell assay.
More Information Supplier PageA419259 trihydrochloride is an apoptosis inducing agent that inhibits Src family kinases (c-Src).
More Information Supplier PageA419259 trihydrochloride is an apoptosis inducing agent that inhibits Src family kinases (c-Src).
More Information Supplier PageA419259 trihydrochloride is an apoptosis inducing agent that inhibits Src family kinases (c-Src).
More Information Supplier Pagea5IA is a nootropic drug invented in 2004 by a team working for Merck, Sharp and Dohme.
More Information Supplier Pagea5IA is a nootropic drug invented in 2004 by a team working for Merck, Sharp and Dohme.
More Information Supplier Pagea5IA is a nootropic drug invented in 2004 by a team working for Merck, Sharp and Dohme.
More Information Supplier PageThe S-enantiomer of A66 is a potent inhibitor of the p110alpha isoform of PI 3-kinase (PIK3CA).
More Information Supplier PageThe S-enantiomer of A66 is a potent inhibitor of the p110alpha isoform of PI 3-kinase (PIK3CA).
More Information Supplier PageThe S-enantiomer of A66 is a potent inhibitor of the p110alpha isoform of PI 3-kinase (PIK3CA).
More Information Supplier PageThe S-enantiomer of A66 is a potent inhibitor of the p110alpha isoform of PI 3-kinase (PIK3CA).
More Information Supplier PageThe S-enantiomer of A66 is a potent inhibitor of the p110alpha isoform of PI 3-kinase (PIK3CA).
More Information Supplier PageAAF-CMK is a serine protease inhibitor which irreversibly inhibits TPPII (tripeptidyl peptidase II), a giant protease which may substitute for some proteasome functions1, and reversibly inhibits Cln2 (TPPI).
More Information Supplier PageAAF-CMK is a serine protease inhibitor which irreversibly inhibits TPPII (tripeptidyl peptidase II), a giant protease which may substitute for some proteasome functions1, and reversibly inhibits Cln2 (TPPI).
More Information Supplier PageAAF-CMK is a serine protease inhibitor which irreversibly inhibits TPPII (tripeptidyl peptidase II), a giant protease which may substitute for some proteasome functions1, and reversibly inhibits Cln2 (TPPI).
More Information Supplier PageAB-FUBINACA was first synthesized by Pfizer as a potent CB1 receptor modulator for potential therapeutic use, but recently was identified along with AB-PINACA (Item No. 14038) in illegal herbal products.
More Information Supplier PageAB-FUBINACA was first synthesized by Pfizer as a potent CB1 receptor modulator for potential therapeutic use, but recently was identified along with AB-PINACA (Item No. 14038) in illegal herbal products.
More Information Supplier PageAB-FUBINACA was first synthesized by Pfizer as a potent CB1 receptor modulator for potential therapeutic use, but recently was identified along with AB-PINACA (Item No. 14038) in illegal herbal products.
More Information Supplier PageAB-FUBINACA was first synthesized by Pfizer as a potent CB1 receptor modulator for potential therapeutic use, but recently was identified along with AB-PINACA (Item No. 14038) in illegal herbal products.
More Information Supplier PageAB05831 is a highly potent and specific inhibitor of beta-hexosaminidase.
More Information Supplier PageAB05831 is a highly potent and specific inhibitor of beta-hexosaminidase.
More Information Supplier Page
